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One-third of the world’s population has been infected with Mycobacterium tuberculosis
(M. tuberculosis), a primary pathogen of the mammalian respiratory system, while
about 10% of latent infections progress to active tuberculosis (TB), indicating that
host and environmental factors may determine the outcomes such as infection
clearance/persistence and treatment prognosis. The gut microbiota is essential for
development of host immunity, defense, nutrition and metabolic homeostasis. Thus, the
pattern of gut microbiota may contribute to M. tuberculosis infection and prognosis.
In current study we characterized the differences in gut bacterial communities in new
tuberculosis patients (NTB), recurrent tuberculosis patients (RTB), and healthy control.
The abundance-based coverage estimator (ACE) showed the diversity index of the
gut microbiota in the patients with recurrent tuberculosis was increased significantly
compared with healthy controls (p < 0.05). At the phyla level, Actinobacteria and
Proteobacteria, which contain many pathogenic species, were significantly enriched
in the feces RTB patients. Conversely, phylum Bacteroidetes, containing a variety
of beneficial commensal organisms, was reduced in the patients with the recurrent
tuberculosis compared to healthy controls. The Gram-negative genus Prevotella of oral
origin from phylum of Bacteroidetes and genus Lachnospira from phylum of Firmicutes
were significantly decreased in both the new and recurrent TB patient groups, compared
with the healthy control group (p < 0.05). We also found that there was a positive
correlation between the gut microbiota and peripheral CD4+ T cell counts in the
patients. This study, for the first time, showed associations between gut microbiota
with tuberculosis and its clinical outcomes. Maintaining eubiosis, namely homeostasis
of gut microbiota, may be beneficial for host recovery and prevention of recurrence of
M. tuberculosis infection.
Keywords: gut microbiota, pulmonary tuberculosis, microbial diversity, Mycobacterium tuberculosis, new
tuberculosis, recurrent tuberculosis
INTRODUCTION
Tuberculosis (TB) is a chronic potentially fatal infectious disease caused by Mycobacterium
tuberculosis (M. tuberculosis). Approximately one-third of the world population has been infected
with M. tuberculosis. While most of the initially infected individuals recover from infection
through immune clearance, about only 5–10% develop active/chronic tuberculosis, implying
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that host and environmental factors are critical in determining
the outcomes of M. tuberculosis infection, including drug
resistance and recurrence (Tuberculosis Programme and World
Health Organization, 2015). Other environmental factors
make people more susceptible to tuberculosis infection. One
important risk factor globally is human immunodeficiency virus
(HIV), which generates immunosuppression and tolerance for
the M. tuberculosis. Malnutrition, poverty, under privileged
communities also contribute to the high incidence of active
M. tuberculosis infections, again showing critical roles of
environmental factors in the patho-physiological development
for infection/transmission and prognosis of M. tuberculosis.
Thus, identification of other environmental factors is valuable for
treatment and prevention of tuberculosis infection, persistence,
and recurrence.
The gut microbiome or intestinal flora is essential for the
host through variety of biological functions. For instance, well
established evidence shows that gut microbiome is critical
for (1) development of host immune system, (2) harvesting
energy from diet, (3) production of vitamin B series, (4)
protection against foreign microbe invasion, (5) bile acid
turnover, (6) regulation of satiety, (7) and metabolic homeostasis
(Macpherson and Harris, 2004; Larsen et al., 2010). Conversely,
host factors, mostly through innate and adaptive immunities
such as epithelial secreted defensins and IgA and mucosa in
turn impact and maintain gut microbiome in homeostasis,
namely “eubiosis.” On the other hand, imbalanced microbiota,
called “dysbiosis,” promotes a variety of degenerative diseases
including obesity, diabetes, fatty liver diseases, cirrhosis, and
certain cancers (Backhed et al., 2005; Larsen et al., 2010; Qin et al.,
2014).
About 40% of the total body pool of lymphocytes are
located in the intestine, suggesting a key role of the gut
microbiota in generating the immune system and functionality
(Grice and Segre, 2012). Since the gut microbiome is critical
for the metabolic homeostasis of the host, we reasoned
that the gut microbiota may impact on M. tuberculosis
infection and prognosis. Here, we report initial findings
showing the alternation of gut microbiota and association
with tuberculosis prognosis among the new and recurrent
patients. The findings from this work may lead to a better
understanding of the role of gut microbiota in outcomes of
tuberculosis and may provide new methods for tuberculosis
treatments.
METHODS
Ethics Statement
This study protocol was approved by the Ethics Review
Committee of the Chengdu Public Health and Therapeutic
Center. Written informed consent was obtained from all
participants.
Abbreviations: MTB, Mycobacterium tuberculosis; NTB, new tuberculosis
patients; RTB, recurrent tuberculosis patients; OTU, operational taxonomic unit;
PCA, principal component analysis; PCR, polymerase chain reaction.
Patient Information
Pulmonary tuberculosis was diagnosed using the tuberculosis
diagnosis and treatment guidelines (2013, China), which include
the imaging examination, clinical symptoms, physical signs,
laboratory tests, medical history, progress notes and other
complications.
Study Design and Patient Samples
A total of 37 pulmonary tuberculosis patients (19 NTB and 18
RTB) and 20 healthy controls were initially enrolled from July
2015 to June 2016. We divided the tuberculosis patients into
two groups according to the following criteria. New tuberculosis
group (NTB) is defined for the subjects with newly developed
pulmonary tuberculosis, which had been no more than 1-
week anti-tuberculosis treatment. Recurrent tuberculosis group
(RTB) was defined as pulmonary tuberculosis patients who
had previously been treated and declared as cured prior to
becoming once again bacteriologically positive. The healthy
control group consisted of 20 healthy individuals who had
passed tuberculosis tests without evidence of tuberculosis or
other diseases. Exclusion criteria included a history of antibiotic
or probiotic treatment more than 1 week within the previous
8 weeks. All participants provided written informed consent
prior to the study. Information was collected from participants
included age, sex, height, weight, underlying diseases, clinical
manifestations, and laboratory and radiological findings.
Fecal Sample Collection and Microbe DNA
Extraction
Fresh stool samples (200 mg/aliquot) were immediately frozen
on collection and stored at −80◦C before analysis. DNA from
fecal samples was extracted using OMEGA stool DNA mini kit
(OMEGA, China).
High-Throughput Sequencing Analysis
The 16S ribosomal RNA (rDNA) gene was analyzed by using
IlluminaMiseq (Novogene Bioinformatics Technology Co., Ltd.,
USA). DNA was diluted to 1 ng/µL using sterile water. The
16S rRNA genes of distinct regions (16S V4) were amplified
used specific primer 515F (5′-GTGCCAGCMGCCGCGGTAA-
3′) and 806R (5′-GGACTACHVGGGTWTCTAAT-3′) with the
barcode. All PCR reactions were carried out with Phusion R©
High-Fidelity PCR Master Mix (New England Biolabs, USA).
Samples of PCR products were mixed 1:1 (vol:vol) with
loading buffer (contained SYBR green) followed by performing
electrophoresis on 2% agarose gel. Samples with illuminated with
SYBR green between 400 and 450 bp were chosen for further
experiments. The PCR products were purified with Qiagen Gel
Extraction Kit (Qiagen, Germany). Sequencing libraries were
generated usingTruSeq R© DNA PCR-Free Sample Preparation
kit (Illumina, USA) following manufacturer’s recommendations
with index codes. The quality of library was assessed by
Qubit@ 2.0 Fluorometer and Agilent Bioanalyzer 2100 system
(Thermo Scientific, USA). Then, the library was sequenced on an
IlluminaHiSeq2500 platform and 250 bp paired-end reads were
generated.
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CD4+ T Cell Measurement
Whole blood samples were consecutively collected by
venipuncture from the subjects. CD4+ T-cell enumeration
was performed on CyFlow Counter (Beckman Coulter FC_500,
USA) and data was analyzed by CXP analysis software.
Bioinformatics Analysis and Statistics
Sequence analyses were performed by Uparse software (Uparse
v7.0.1001, http://drive5.com/uparse/). Sequences with ≥97%
similarity were assigned to the same Operational Taxonomy
Units (OTUs). The representative sequence for each OTU
was screened for further annotation. For each representative
sequence, the GreenGene Database (http://greengenes.lbl.gov/
Download/OTUs/) was used based on Ribosomal Database
Project (RDP) classifier (Version 2.2, http://sourceforge.net/
projects/rdp-classifier/) for algorithm to annotate taxonomic
information. The abundance information was determined using
a standard of sequence number corresponding to the sample
with the least sequences. Alpha diversity in the samples was
calculated with QIIME (Version 1.7.0). Beta diversity (Chao1 or
Simpson index or Shannon index) analysis was used to evaluate
differences of samples in species complexity. Beta diversities
on both weighted and un-weighted unifrac were calculated by
QIIME software. PCoA analysis was displayed by WGCNA
package.
The Mann-Whitney test was used to evaluate the difference
of BMI between the patients and the control group (GraphPad
Prism software Version 6.01, USA). The differences in relative
abundance were analyzed by the T-test (R software Version
2.15.3). The correlation between relative abundance and CD4+
T cells and specific microbes was computed using Spearman
Ranking Correlation (GraphPad Prism software Version 6.01).
RESULTS
Human Subject Characteristics
To assess the fecal microbiota in the patient groups, we
initially enrolled 37 tuberculosis patients (19 patients had new
tuberculosis as NTB, and 18 patients recurrent tuberculosis as
RTB) and 20 healthy controls. Detailed characteristics of enrolled
participants are given in Table 1. Age was similar between the
tuberculosis patients (45.1y for NTB, 46.6 for RTB), but differed
from the healthy controls (35.3y). There was a higher percentage
of male individuals in the patient groups (male: female = 15:3).
The median body mass index (BMI) was significantly lower in
both the NTB group (19.1) and the RTB group (19.0), compared
with the healthy individuals (22.8, Mann-Whitney test, p< 0.01).
The sputum smear positive and sputum-culture positive rates
were higher in the patients in the RTB group than that in the
in the NTB group. There were 6 multi-drug resistance (MDR)
patients in the RTB group, but none in the NTB group.
Overview of Gut Bacterial Diversities in the
New and Recurrent Tuberculosis Groups,
and the Control Human Subjects
To analyze the microbiota for their association with patients with
new tuberculosis and the recurrent tuberculosis in comparison
with that from the healthy controls, 57 fecal samples were
TABLE 1 | Population characteristics.
TB patients Health controls
New
tuberculosis
(n = 19)
Recurrent
tuberculosis
(n = 18)
(n = 20)
Age; median
(range in years)
45.1 (14–75) 46.6 (15–77) 35.1 (25–66)
Gender
Male 10 15 12
Female 9 3 8
Male/Female 1.1 5.0 1.5
Body mass index
(BMI)
19.1 ± 2.6* 19.0 ± 1.4* 22.8 ± 1.5
Smear positive (%) 7 (36.8) 14 (77.8) –
Sputum-culture
positive (%)
11 (57.9) 16 (88.9) –
Drug Susceptibility Pattern (%)
MDR-TB 0 6 (33.3) –
Data are expressed as the mean ± SD. MDR-TB, multidrug-resistant tuberculosis. The U
Mann–Whitney test was used to evaluate the two groups. *P < 0.01, significant difference
in comparison with the healthy control group.
subjected to 16S rDNA gene sequencing analysis. A total
number of 1,951,408 high-quality 16S rDNA gene sequencing
tags (average 52,740 per sample) were processed from 37 stool
samples of patients with active tuberculosis. Among them, we
identified an average of 632 OTUs (the operational taxonomic
unit, which is equivalent to bacterial species) for the NTB,
and an average of 675 OTUs were identified for the recurrent
group. For the 20 samples in the healthy control group, we
generated 1,083,132 sequencing tags (average 54,157 per sample),
which gave 533 OTUs (Table 2). Thus, the results suggested that
M. tuberculosis infection is related to the increased biodiversity of
the gut microbiome in the two tuberculosis groups.
We then thoroughly assessed the overall diversity through the
parameters of the Abundance-based Coverage Estimator (ACE-
diversity index), Chao1-diversity index, the Simpson index, and
Shannon-diversity index. The alpha-diversity, which is the mean
species diversity in gut, showed that the fecal microbiota from
the recurrent tuberculosis was notably different compared to the
control. The ACE-diversity index in the patients in the NTB
was moderately greater than that in the control group, but
the index for the recurrent group was statistically greater than
that in the healthy control group (Figure 1A, Wilcox test, p <
0.01). The Chao1-diversity index was moderately increased in the
two groups of tuberculosis patients (Figure 1B). The Simpson
index was used to measure the degree of concentration when
individuals were classified into types, and Shannon index was
used to quantify the uncertainty (Figures 1C,D). There were no
significant differences among the groups in terms of the Simpson
and Shannon indexes.
The unweighted principal component analysis (unifracPCoA)
indicated that the fecal microbial communities were different
among the three groups. However, the pattern of microbiota
in the new tuberculosis was relatively close to that of the
control group, while the recurrent group had a greater difference
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TABLE 2 | 16S rRNA DNA sequencing data summary.
TB Patients Healthy controls
New tuberculosis
(n = 19)
Recurrent tuberculosis
(n = 18)
(n = 20)
Total_tag 52,565 ± 6,905 52,925 ± 9,307 54,157 ± 6,094
Unique_tag 710 ± 356 863 ± 415 751 ± 354
OTUs 632 ± 223 675 ± 237 533 ± 126
Data are expressed as the mean ± SD.
from the new and the control groups (Figure 2A). Although
a few samples overlapped, the two tuberculosis groups had
significantly greater PCA variation than that in the control group
(Figures 2B,C, Wilcox test, p < 0.01). The results from the
PCA analysis are consistent with the increased alpha-diversity as
shown in the Figure 1.
The Bacteria Differ Significantly among the
Three Groups
Among the 10 most abundant bacterial phyla, the relative
abundance of the phyla Bacteroidetes, which is the largest
component of gut microbe with more than 50% of the total
abundance and contains many beneficial commensal organisms,
was decreased in the two groups of tuberculosis in comparison
with the healthy controls (Figure 3A). Firmicutes, the second
largest phylum of gut microbe, was moderately decreased in the
RTB, but was without significant change between the new group
and the control group. Importantly, phylum Proteobacteria,
which contain many Gram-negative bacteria and opportunistic
pathogenic species, was significantly increased 2-fold in the new
group, and 4-fold in the RTB in comparison with that in the
control group (CG). At the bacterial genus level (Figure 3B),
Bacteroides was without significant difference between the two
tuberculosis groups (29.6% in CG, 28.4% in NTB, 31.0% in
RTB). Genus Prevotella was significantly decreased in the two
tuberculosis groups (22.5% in CG, 6.2% in NTB, 7.3% in RTB).
Conversely, genera Escherichia was massively increased in both
tuberculosis groups (0.8% in CG, 6.3% in NTB, 7.1% in RTB); and
Streptococcus gave a similarly increased in the two tuberculosis
groups (0.2% in CG, 5.6% in NTB, 1.4% in RTB).
To further understand the microbial communities among
those groups, we compared the relative abundance at the bacterial
phyla and genus levels among the three groups. At the bacterial
phyla levels, the NTB (Figure 3C) demonstrated a marked
decrease of Bacteroidetes in comparison with the control group
(44.1 vs. 58.8%, p = 0.020). However, the phylum Proteobacteria
was significantly enriched in the two tuberculosis groups: 11.7%
of Proteobacteria for NTB vs. 4.0% for the CG, (p = 0.017),
and 15.8% of Proteobacteria in the RTB vs. 4.0% in the CG, (p
= 0.001). Likewise, a similar trend was observed for phylum
Actinobacteria in the NTB (0.5% NTB vs. 0.2% CG, p = 0.015)
and the RTB (4.0% vs. 1.1%, p= 0.021).
As shown in the Figure 3D, the bacterial communities were
further compared at the genus level. Genus Prevotella, which
is affiliated with the phylum Bacteroidetes, was significantly
decreased in the NTB over the control (6.2% NTB vs. 22.5%
CG, p = 0.005); and the patients with RTB (7.3% vs. 22.5%, p
= 0.010). Genus Lachnospira within the phylum Firmicutes was
markedly decreased in the NTB (0.9% NTB vs. 2.7%CG, p =
0.010) and in the recurrent group compared with healthy control
group (0.6%RTB vs. 2.7%CG, p= 0.003). The relative abundance
of Roseburia within the phylum Firmicutes, which is a group of
major “short chain fatty acids” (SCFA) producing microbe, was
significantly reduced in the new tuberculosis (0.5% NTB vs. 1.5%
CG, p = 0.008). SCFA are well known for their functions in
innate immunity and energy homeostasis (Schauber et al., 2003;
Lu et al., 2016). Coprococcus, also within the phylum Firmicutes,
was mostly depleted in the patients in the new group compared
with the control group (0.5% NTB vs. 1.1% CG, p = 0.012).
However, genus Escherichia within the phylum Proteobacteria
(7.0% RTB vs. 0.1% CG, p = 0.041) and Collinsella (0.1% RTB
vs. 0.03% CG, p= 0.042) within the phylum Actinobacteria, were
enriched in the recurrent group. Nevertheless, bacteria groups in
Figure 3D did not show any statistical difference between the two
tuberculosis groups.
Gut Bacteria as Biomarkers in the New and
Recurrent Tuberculosis
To identify key biomarkers differentially displayed between
the two tuberculosis groups, we performed a statistical analysis
using LEfSe analysis with LDA to characterize different species
between the groups. A total of 14 taxa were identified that
were significantly different between the groups (Figure 4). The
recurrent group (RTB) showed the most unique microbiota
by a higher abundance of Proteobacteria (phylum), Gamma-
Proteobacteria (class within Proteobacteria), Enterobacteriales
(order within Proteobacteria), Enterobacteriaceae (order within
Proteobacteria), Cyanobacteria (phylum) and Verrucomicrobia
(phylum). We found that the abundance of family Bacilli–
Lactobacillales-Lactobacillaceae was higher in the two
tuberculosis groups.
Relative Abundance of Genus Prevotella
and LachnospiraWas Associated with
Patient’s Peripheral CD4+ T Cell Counts
CD4+ lymphocytes are the major adaptive immune cells for
infective responsiveness. We explored the potential association
between the fecal microbiota and CD4+ cells in the two types
of tuberculosis. We applied nonparametric Spearman’s rank
correlation coefficients tomeasure the relative abundance ofmost
enriched and least enriched bacterial taxa with the peripheral
CD4+ cell counts in the two types of patients. Provotella, Gram-
negative bacteria that are members of the oral and vaginal flora,
are often recovered from anaerobic infections of the respiratory
tract. We found that Prevotella at the genus level (p = 0.025)
were strongly and positively correlated with CD4+ cell counts in
patients with NTB (Figure 5A). Conversely, in the RTB, the gut
Prevotella levels exhibited a negative association with CD4+ cell
counts (Figure 5B).
Gut Lachnospira was positively related to CD4+ counts
in the NTB, but was negatively related to CD4+ counts in
the RTB (Figures 5A,B). Genus Streptococcus, Veillonella and
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FIGURE 1 | Altered biodiversity of gut microbiota in the new and recurrent tuberculosis patients in comparison with healthy control. (A,B) The new TB patients (NTB,
n = 19), recurrent TB group (NTB, n = 18), and healthy human subjects, control (CG) are described in the Methods and Materials. The alpha-diversity, richness of gut
microbes, was determined by ACE index and Chao1 index. (C,D) The ecological diversity of gut microbiota in the three groups of human subjects was measured by
Simpson index and Shannon index. The p-values were calculated using Wilcox test. Statistical significance is displayed as *p < 0.05.
FIGURE 2 | The beta-diversity of the microbial communities in the new and recurrent tuberculosis patients and the healthy control. (A) Principal Coordinates Analysis
(PCoA) plot based on unweighted UniFrac distance. Each dot represents one sample from each group. (B) Beta-diversity index difference based on unweighted
UniFrac. (C) Beta-diversity index difference based on weighted UniFrac. The p-values were calculated using Wilcox test. Statistical significance is displayed as
**p < 0.01.
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FIGURE 3 | The major gut bacterial phyla and genus in new and recurrent tuberculosis patients as well as the healthy control. (A) Bacterial phylum levels of new and
recurrent tuberculosis groups, NTB and RTB respectively. (B) Bacterial genus levels. (C) Comparison of gut microbiota of relative abundance at the bacterial phylum
levels. (D) Comparison of gut microbiota of relative abundance at genus levels. The p-values were calculated using T-test, and significance was compared against the
CG. *P < 0.05. **P < 0.01.
Escherichia showed no clear correlation with the CD4+ cells in
the tuberculosis patients. We also analyzed the three bacterial
taxa, which are indicative of dysbiosis at the species levels,
Veillonella dispar, Prevolellacopri, Escherichia coli, and none
of them showed reliable correlation with CD4+ cell counts
(Figures 5C,D).
DISCUSSION
The gut microbiota, through intimate interaction with host
intestinal epithelial cells, co-evolves with the host. To some
extent, the gut microbiota is regarded as an essential “organ”
for the host. For example, gut microbes as an antigen source
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FIGURE 4 | Different species as biomarkers in relative abundance identified by LEfSe analysis between the two groups of tuberculosis patients and the healthy
control. (A) The length of the column represents the influence of significantly different species in relative abundance (LDA scores > 4). (B) The significantly different
species are shown in the clado-gram. Each circle represents phylogenetic level from phylum to genus inside to outside. Each circle’s diameter is proportional to the
taxon’s abundance and biomarker is consistent with the group marked with color. Red in CG, green in NTB, and blue in RTB.
configure the early age development of the immune system for
the host. The enterotype of gut microbiota is influenced by
genetic and epigenetic factors from the host, the dietary and
nutrition composition, and environmental factors. Gut microbes
are known a major source of vitamin B series which serve as the
co-factors in metabolic pathways. On the other hand, commensal
microbiota, through production of antagonizing agents such
as lantibiotics, can efficiently expel foreign invasion from the
host. In return, the host provides protection for the beneficial
symbiotic gut microbes. For instance, we recently demonstrated
that vitamin D signaling through regulation of Paneth cell alpha-
defensins promotes gut microbiota eubiosis, which consequently
inhibits the high-fat-diet-induced metabolic disorders and fatty
liver (Su et al., 2016).
M. tuberculosis has a great capacity to escape immune
surveillance and can promote immune tolerant granulomata to
protect the pathogens from immune clearance. The majority
of M. tuberculosis exposed individuals remain asymptomatic
but exhibit varying levels of immunity against M. Tuberculosis
infection, indicating host factors determining the outcomes
of the infection. In an animal model, one recent report
showed changing gut microbiota during the M. Tuberculosis
infection (Winglee et al., 2014). Also, in a murine infection
model, another recent report showed that the oral antibiotic-
mediated gut dysbiosis could promote M. tuberculosis infection
and dissemination (Khan et al., 2016). Conversely, the report
showed that fecal transplant of microbes from the control mice
attenuated M. tuberculosis infection and improve prognosis.
Short chain fatty acids (SCFAs), as a major group of metabolites
from gut microbes, are essential for host immunity such as
Treg induction and protection of gut epithelia, in addition
to providing an energy source (Lin et al., 2015; Asarat
et al., 2016; Correa-Oliveira et al., 2016). One report showed
butyrate could antagonize the M. tuberculosis-induced pro-
inflammatory response in macrophages and concomitantly
promote IL-10 expression (Lachmandas et al., 2016). However,
clinical evidence remains largely unknown for the association
between gut microbiota andM. tuberculosis infection, prognosis,
and recurrence. A recent report showed that colonization
with Helicobacter is concomitant with modified gut microbiota
and drastic failure of the immune control of Mycobacterium
tuberculosis (Majlessi et al., 2017).
In the present study, through 16S rDNA gene sequencing
analysis we initially measured gut bacterial communities in
new and recurrence of tuberculosis infections; and associate gut
microbiota with M. tuberculosis infection and recurrence. Our
results showed that the gut microbiota are significantly different
in the two types of tuberculosis and the healthy control groups.
We further found that specific changes in the gut microbiota
were associated with patient’s peripheral CD4+ T cell counts. To
our knowledge, this is the first documentation of changing gut
microbiota with theM. tuberculosis infection and recurrence.
Specifically, we found the ACE-diversity index was increased
significantly in the recurrent tuberculosis; and the un-weighted
unifracPCoA in that group was notably different from the control
group. In agreement with our finding, one report showed that
the microbiota in the sputum of pulmonary tuberculosis patients
were more diverse than those of healthy participants (Cui et al.,
2012). Furthermore, in the sputum, many foreign bacteria were
unique to pulmonary tuberculosis patients. Another study found
that Proteobacteria and Bacteroidetes were more represented in
the sputum of tuberculosis samples, while Firmicutes was more
predominant in the controls (Cheung et al., 2013).
We also investigated the gut microbial composition at
different phylogenic levels for their relationship with the
tuberculosis groups. We found that Proteobacteria and
Actinobacteria were enriched, while Bacteroidetes was mostly
depleted at the phyla levels in the patients with tuberculosis
recurrence. This change is consistent with previous studies
conducted in sputum (Wu et al., 2013). Genus Prevotella, which
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FIGURE 5 | Correlation between the relative abundance of Prevotella, Lachnospira, Streptococcus, Veillonella, Escherichia with blood CD4+ T cell counts. Taxa of
bacteria at the genus level were further analyzed at each of patient group. (A,C) The new tuberculosis group. (B,D) The recurrent tuberculosis group. X axis denotes
the CD4+ T cell counts/µl. The assessment was done with Spearman’s rank order correlation. Black dots indicate data.
is affiliated with the phylum Bacteroidetes and genus Lachnospira
within the phylum Firmicutes were significantly decreased in
both tuberculosis patient groups. The genus Lachnospiras and
Roseburia, both within the phylum Firmicutes, have been known
for their production of short-chain fatty acids (SCFAs) (Duncan
et al., 2007; Berni Canani et al., 2012). Here, we noticed the
reduction of genus Lachnospiras and Roseburiain in the two
groups of tuberculosis patients, indicating potential impairment
of SCFA production and the consequent metabolic disorders,
which may further impact on the tuberculosis infection and
prognosis, a topic under our investigation (Supplementary
Figure S1). The functions of butyrate are known for promoting
intestinal health in part through maintaining the integrity of
the intestinal mucosa (Roy et al., 2006) and regulation of host
immune response (Maslowski et al., 2009). We also found that
Escherichia coli, which is affiliated with the Proteobacteria was
enriched in patients with RTB. Interestingly, the genus Prevotella
was decreased in both tuberculosis groups.
Another interesting finding was that Prevotella positively
correlated with the peripheral CD4+ cells in new tuberculosis
cases, and inversely correlated with recurrent tuberculosis cases.
A similar trend was found for Lachnospira. These data suggest
a new hypothesis that specific gut microbes may associate with
host’s immune status and related to prognosis and outcome of
patients. The specific gut microbes in the tuberculosis patients
need to be further identified and characterized as potential
biomarkers for the tuberculosis prognosis.
Type-2 diabetes mellitus confers a 3-fold of increased risk for
tuberculosis. How diabetes promotes M. tuberculosis infection
and dissemination is a big clinical challenge, and gut microbes
could be the key mediators between diabetes and tuberculosis.
Increased phylum of Proteobacteria and decreased phylum
of Bacteroidetes had been well documented in diabetes and
obesity (Ley et al., 2005; Turnbaugh et al., 2009). One recent
study showed the influence of physiological concentrations of
butyrate on cytokine responses to M. tuberculosis in human
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peripheral blood mononuclear cells (PBMCs) (Lachmandas
et al., 2016). The study found that butyrate suppressed the
tuberculosis-induced proinflammatory cytokine responses, while
it increased production of IL-10, an immune regulatory cytokine.
Altered gut microbiota may also contribute to the recurrence of
tuberculosis. Recurrent tuberculosis creates substantial burden
for tuberculosis, and it may arise through relapse of the original
infection or through reinfection with a new strain. High rate of
relapse is often associated with unsuccessful treatment and drug
resistance. A high rate of recurrence due to reinfection implies
a failure to develop protective immunity after the first episode
and is often related to human immunodeficiency virus infection,
while other factors may contribute as well. Whether and how
the altered gut microbiota contributes to recurrence is an urgent
problem that requires attention.
This initial clinical study should be extended and refined.
First, a major and common challenge for a clinical study shared
by the current one is to recruit the participants with similar
backgrounds and characteristics. Another common limitation
shared by our study is the small number of human subjects. Our
results will require validation in larger cohort studies.
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